Ludwig-Maximilians - University of Munich
lmu.deTotal trials
221
Active
26
Phase 3
21
Total enrollment
83,166
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Irinotecan | — | — | — | — | 7 | ||
| 5-FU | — | — | — | — | 6 | ||
| Folinic Acid | — | — | — | — | 5 | ||
| Atezolizumab Injection, Bevacizumab | — | — | — | — | — | 1 | |
| Panitumumab | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 |
Next readouts
- 2024-08-01
- 2025-03-01
- 2030-07
Top conditions
- Depression12
- Depressive Disorder10
- Depression in Adolescence9
- Schizophrenia6
- Metastatic Colorectal Cancer5
- Ischemic Stroke5
- Quality of Life5
- Healthy5
Frequently asked questions about Ludwig-Maximilians - University of Munich
- How many clinical trials does Ludwig-Maximilians - University of Munich have on ClinicalTrials.gov?
- Ludwig-Maximilians - University of Munich is listed as the lead sponsor on 221 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ludwig-Maximilians - University of Munich's trials are in Phase 3?
- 21 of Ludwig-Maximilians - University of Munich's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Ludwig-Maximilians - University of Munich focus on?
- Ludwig-Maximilians - University of Munich's most-studied conditions on ClinicalTrials.gov are Depression, Depressive Disorder, Depression in Adolescence, Schizophrenia, Metastatic Colorectal Cancer.
- When are Ludwig-Maximilians - University of Munich's next clinical trial readouts?
- Ludwig-Maximilians - University of Munich has 3 upcoming primary-completion readouts tracked here; the soonest is “Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation”, expected around 2024-08-01.